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Maintaining energy balance involves the dynamic control of appetite and energy expenditure. A new
study from the Kadowaki laboratory (Kubota et al., 2007) shows that the adipocyte-derived hormone
adiponectin increases appetite and reduces energy expenditure by stimulating AMPK in the
hypothalamus.The hypothalamus integrates signals
from the gut and white adipose tissue
that regulate appetite and control
energy expenditure and metabolism
through sympathetic outflows to mus-
cle, fat, and liver (Xue and Kahn, 2006).
These signals stem from hormones
secreted from adipose tissue (leptin,
adiponectin, IL-6), the gut (ghrelin,
cholecystokinin, peptide YY), and pan-
creas (insulin) as well as nutrient sig-
nals such as free fatty acids, glucose,
and branched-chain amino acids
(Xue and Kahn, 2006). For example,
leptin acts centrally at the hypothala-
mus to suppress appetite and increase
energy expenditure in skeletal muscle
(Minokoshi et al., 2004). Indeed,
rodents and humans lacking leptin or
its receptor become obese as a result
of the failure of these mechanisms.
Treating rodents with adiponectin
also increases glucose and fat metab-
olism in muscle (Fruebis et al., 2001),
reduces glucose production by the
liver, and leads to improvements in
insulin sensitivity (Combs et al.,
2001). In this issue of Cell Metabolism,
Kubota and colleagues (2007) show an
exciting new role for adiponectin in
stimulating appetite and opposing the
actions of leptin in the hypothalamus.
Adiponectin is an abundant circulat-
ing hormone present in at least three
multimeric forms: trimers, hexamers,
and high-molecular-weight (HMW)
complexes, the latter of which appear
to be most biologically active and are
reduced with obesity. Both adiponec-
tin and leptin act via their cell-surface
receptors (AdipoR1/2 and Ob-R,
respectively) to control a common
enzyme called AMPK, which has
been shown to play a critical role inregulating appetite (Andersson et al.,
2004; Minokoshi et al., 2004). Hypo-
thalamic AMPK activity is increased
by fasting and reduced by feeding.
These effects are mediated by
changes in circulating hormones such
that leptin, insulin, and glucose reduce
AMPK activity while the gut-derived
hormone ghrelin increases AMPK
activity. The inhibition of AMPK results
in the suppression of the appetite-
stimulating hormones, neuropeptide
Y (NPY), and agouti-related protein,
whereas activation of AMPK increases
their expression and induces feeding.
Thus, the balance between satiety
and feeding hinges on whether AMPK
is inhibited or activated in the brain.
Compared to their central effects,
some hormones such as leptin (Mino-
koshi et al., 2004) and ciliary neurotro-
phic factor (Watt et al., 2006) act
differently in peripheral tissues and
stimulate AMPK activity. The differen-
tial signaling mechanisms operating
between the brain and peripheral
tissues is poorly understood, but it is
known that AMPK activity is regulated
by changes in nucleotides and is cova-
lently regulated by protein phospha-
tase 2C and at least three upstream
kinases, LKB1, CAMKK2, and TAK1
(Hardie, 2007), with CAMKK2 most
likely dominant in the brain (Hurley
et al., 2005). In skeletal muscle, the
activation of AMPK by adiponectin,
like leptin, stimulates fatty acid oxida-
tion through the AMPK-dependent
phosphorylation of ACC, which in
turn reduces malonyl-CoA and in-
creases mitochondrial b-oxidation,
while in the liver it leads to the sup-
pression of hepatic gluconeogenesis
through phosphorylation of TORC2.Cell MetabMice lacking adiponectin (adipo/)
or its receptor AdipoR1 have impaired
insulin action, but in marked contrast
to leptin-deficient animals, they are
not obese (Kubota et al., 2007). Kubota
et al. show that both receptors
AdipoR1 and AdipoR2 colocalize with
the leptin receptor in the hypothala-
mus and that cerebrospinal fluid
(CSF) contains low levels of adiponec-
tin that comes from the blood. They
find that intravenous injection of adi-
ponectin raises CSF levels in adipo/
mice. The forms of adiponectin found
in the CSF are restricted to the trimeric
and hexameric forms, and not the
HMW form present in blood, and this
may be an important point of differ-
ence between an earlier study in which
HMW recombinant adiponectin was
infused into the brain and induced
weight loss and increased energy
expenditure (Qi et al., 2004). In agree-
ment with previous studies (Andersson
et al., 2004; Minokoshi et al., 2004)
Kubota et al. observed that fasting
increased AMPK activity in the arcuate
hypothalamus (ARH), which was
reversed by refeeding (Figure 1). As
fasting induces changes in a number
of nutrients and hormones, multiple
approaches were used in this study
to link the increased fasting AMPK
activity with elevations in CSF adipo-
nectin. First, when adiponectin hex-
amers were injected directly into the
brain, AMPK activity was increased,
resulting in feeding and a reduction in
energy expenditure. These effects
were eliminated following the abla-
tion of AdipoR1 (AdipoR1 siRNA) or
AMPK signaling (AMPK dominant-
negative). What, then, happens in the
adipo/ mice that lack adiponectin?olism 6, July 2007 ª2007 Elsevier Inc. 3
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PreviewsFigure 1. Appetite Control by Adiponectin
Fasting triggers increased adiponectin in the cerebrospinal fluid (CSF) and activation of AMPK in
the brain, which increases NPY and induces feeding (green arrows). Feeding reduces adiponectin
and lowers appetite (red arrows). In obesity, the capacity to lower adiponectin in response to feed-
ing is suppressed, preventing the switching off of appetite (dashed red arrow). CAMKK2, Ca2+/
calmodulin-dependent protein kinase kinase 2b; ACC, acetyl-CoA carboxylase; FACoA, long-
chain fatty acyl-CoA; NPY, neuropeptide Y; ?, unknown pathway.It turns out that they have reduced
AMPK activity as well as reduced
levels of appetite-controlling NPY fol-
lowing a fast and reduced food intake.
In a final series of experiments, Kubota
et al. took advantage of the knowledge
that leptin decreases AMPK activity
and suppresses food intake and found
that the suppressive effect of leptin on
AMPK activity was reversed by adipo-
nectin injection. Importantly, Kubota
et al. demonstrated that adipo/
mice have much higher sensitivity to
a chronic low dose of leptin. In sum-
mary, these observations support the
idea that adiponectin increases in
response to fasting and promotes
feeding by activating AMPK and inhib-4 Cell Metabolism 6, July 2007 ª2007 Eliting the actions of the appetite sup-
pressor leptin.
Serum adiponectin levels are
reduced in obese humans and ob/ob
mice, which would be expected to
reduce appetite, but there is a problem:
the normal reduction in CSF adiponec-
tin levels accompanying refeeding is
impaired in obese ob/obmice. This im-
plies that in obesity, loss of appetite
control occurs on two fronts: leptin
insensitivity resulting from upregula-
tion of the suppressor of cytokine
signaling 3 (SOCS3) and a reduction
in the ability to switch off AMPK signal-
ing and feeding (Steinberg et al., 2006),
which is now combined with an inabil-
ity to suppress CSF adiponectin levelssevier Inc.and reduce appetite in response to
feeding. The discovery of adiponec-
tin’s role in stimulating appetite has
led Kubota et al. (2007) to propose
a ‘‘fat-centric’’ hypothesis in which
the opposing central actions of leptin
and adiponectin provide a homeostatic
mechanism for maintaining fat levels/
energy stores, with the brain acting
as a wired ‘‘server’’ under the hor-
monal control of the fat cell. An impor-
tant unexplored question with rami-
fications for the present obesity
epidemic is whether obese human adi-
ponectin levels in the CSF behave like
those of the mouse and whether strat-
egies for restoring the capacity of
refeeding to reduce CSF adiponectin
levels in obese individuals can be
devised to switch off appetite.
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